Murphy R, Hammarström S, Samuelsson B, Leukotriene C : A slow reacting substance from murine mastocytoma cells. Proc Natl Acatl Sci US 1979; 76: 4275-9.
Morris H, Taylor G, Pipper P, Tippins J. Structure of slow reacting substance of anaphylaxis from guinea-pig lung. Nature 1980; 285: 104-6.
Pauwels R, Kips J, Joos G. Leukotrienes as therapeutic target in asthma. Allergy 1995; 50: 620-2.
Louis R, Neven I, Quadvlieg V, Bettiol J, Radermecker M. Les cystéinyl-leucotriènes: des médiateurs importants dans l'asthme. Rev Méd Liège 1997; 52: 598-602.
Holgate S, Bradding P, Sampson A. Leukotriene antagonists and synthesis inhibitors: New direction in asthma therapy. J Allergy Clin Immunol 1996; 98: 1-13.
Adelroth E, Morris M, Hargreave F, O'Byme P. Airway responsiveness to leukotriene C4, D4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1986; 315: 4804.
Laitinen L, Laitinen A, Haathela T, et al. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341: 989-90.
Hui K, Barnes N. Lung function improvement in asthma with cysteinyl-leukotriene receptor antayonist. Lancet 1991; 337: 1062-3.
Cloud M, Enas G, Kemp J, et al. A specific LTD/LTE4 receptor antagonist improves pulmonary function in patients with mild chronic, chronic asthma. Am Rev Respir Dis 1989; 140: 1348-53.
Spector S, Smith L, Glass M. Effects of six weeks of therapy with oral doses of ICI 204219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618-23.
Reiss T. Altman L, Chervinky P, et al. Effects of montelukasi (MK-0476), a new potent cysteinyl leukotriene receptor antagonist (LTD4) In patients with chronic asthma. J Allergy Clin Immunol 1996; 98:528-34.
Suissa S, Dennis R, Ernst P, et al. Effectiveness of leukrotriene receptor antagonist zafirlukast for mild to moderate asthma. A randomized, double blind, placebo-controlled Trial. Ann Int Med 1997; 126: 177-83.
Barnes N, Pujet JC. Pranlukast, a novel leukotriene receptor antagonist : Results of the First european. placebo controlled, multicentre clinical study in asthma. Thorax 1997; 52: 523-7.
Tamoaki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high dose inhaled corticosteroid. Am J Respir Crit Care Med 1997; 155: 1235-40.
Israel E, Rubin P, Kemp J, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Int Med 1993; 119: 1059-66.
Liu M, Dubé L Lantaster J. Acute and chronic effects of a 5-lipoxgenase inhibitor in asthma : A 6 month randomized multicenter trial. J Allergy Clin Immunol 1996; 98: 859-71.
Global initiative for asthma. Global strategy for asthma management and prevention NHLBI/WHO workshop report march 1993. National institutes of health. National heart, lung, and blood institute. Publication Number 95-3659, January 1995.
Kane G, Pollice M, Kim C, et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 1996; 97: 646-54.
Grant A. The clinical efficacy of antihistamines in the upper and lower airway. Clin Exp Allergy 1997; 27 (Suppl. 2): 38-46.
Kuitert L, Barnes N. PAF and asthma-time for appraisal? Clin Exp Allergy 1995; 25: 1159-62.
Evans D, Barnes P, Cluzel M, O 'Connor B. Effects of a potent platelet-activating-factor antagonist. SR27417A, on allergen-induced asthmatic response. Am J Respir Crit Care Med 1997; 156: 11-6.
Hozawa S, Haruta Y, Ishioka S, Yamakido M. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. Am J Respir Crit Care Med 1995; 152: 1198-202.
